Zenas BioPharma, Inc. (ZBIO) Form SCHEDULE 13D/A — Aug 17, 2026

SR One Capital Management, LLC and its affiliated investment entities filed a Schedule 13D/A on Zenas BioPharma, Inc. (ZBIO), attaching a Rule 13d-1(k)(1) joint filing agreement that allows the group to report its combined ZBIO ownership through a single Schedule 13D. The agreement, executed on August 17, 2026, was signed by Simeon George, M.D., managing member of SR One Capital Management, on behalf of the manager and six affiliated fund vehicles, including SR One Capital Partners II, LP, AMZL, LP, and the SR One Opportunities funds. A limited power of attorney attached as Exhibit 2 appoints Sasha Keough, Karen Narolewski-Engel, James Macadam, and Alexander M.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.